JP2021534138A5 - - Google Patents
Info
- Publication number
- JP2021534138A5 JP2021534138A5 JP2021507456A JP2021507456A JP2021534138A5 JP 2021534138 A5 JP2021534138 A5 JP 2021534138A5 JP 2021507456 A JP2021507456 A JP 2021507456A JP 2021507456 A JP2021507456 A JP 2021507456A JP 2021534138 A5 JP2021534138 A5 JP 2021534138A5
- Authority
- JP
- Japan
- Prior art keywords
- xrpd
- peaks
- omecamutib
- cukα irradiation
- pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024090471A JP2024123028A (ja) | 2018-08-17 | 2024-06-04 | オメカムチブメカルビルの塩及び結晶形態 |
| JP2025066074A JP2025108571A (ja) | 2018-08-17 | 2025-04-14 | オメカムチブメカルビルの塩及び結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765090P | 2018-08-17 | 2018-08-17 | |
| US62/765,090 | 2018-08-17 | ||
| PCT/US2019/046726 WO2020037164A1 (en) | 2018-08-17 | 2019-08-16 | Salts and crystal forms of omecamtiv mecarbil |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090471A Division JP2024123028A (ja) | 2018-08-17 | 2024-06-04 | オメカムチブメカルビルの塩及び結晶形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534138A JP2021534138A (ja) | 2021-12-09 |
| JP2021534138A5 true JP2021534138A5 (enExample) | 2022-08-22 |
Family
ID=67809688
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507456A Pending JP2021534138A (ja) | 2018-08-17 | 2019-08-16 | オメカムチブメカルビルの塩及び結晶形態 |
| JP2024090471A Withdrawn JP2024123028A (ja) | 2018-08-17 | 2024-06-04 | オメカムチブメカルビルの塩及び結晶形態 |
| JP2025066074A Pending JP2025108571A (ja) | 2018-08-17 | 2025-04-14 | オメカムチブメカルビルの塩及び結晶形態 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024090471A Withdrawn JP2024123028A (ja) | 2018-08-17 | 2024-06-04 | オメカムチブメカルビルの塩及び結晶形態 |
| JP2025066074A Pending JP2025108571A (ja) | 2018-08-17 | 2025-04-14 | オメカムチブメカルビルの塩及び結晶形態 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11465969B2 (enExample) |
| EP (1) | EP3837009A1 (enExample) |
| JP (3) | JP2021534138A (enExample) |
| AU (2) | AU2019321573B2 (enExample) |
| CA (1) | CA3108800A1 (enExample) |
| MA (1) | MA53226A (enExample) |
| MX (2) | MX2021001792A (enExample) |
| WO (1) | WO2020037164A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0512193B8 (pt) | 2004-06-17 | 2021-05-25 | Cytokinetics Inc | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal |
| AU2014240049C1 (en) | 2013-03-14 | 2019-03-07 | Amgen Inc. | Heterocyclic compounds and their uses |
| US11040956B2 (en) | 2017-06-30 | 2021-06-22 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| LT3645002T (lt) | 2017-06-30 | 2025-02-10 | Amgen Inc. | Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais |
| UY37879A (es) | 2017-09-13 | 2019-03-29 | Amgen Inc | Compuestos de bisamida que activan el sarcómero y sus usos |
| HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| JP2021534138A (ja) * | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| WO2021053175A1 (en) * | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053189A1 (en) * | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220402874A1 (en) * | 2019-10-09 | 2022-12-22 | Dr. Reddy's Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| TW202233189A (zh) | 2020-11-12 | 2022-09-01 | 美商安進公司 | 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法 |
| WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| BRPI0512193B8 (pt) | 2004-06-17 | 2021-05-25 | Cytokinetics Inc | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal |
| ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| AU2014240104B2 (en) | 2013-03-14 | 2018-11-08 | Amgen Inc. | Heterocyclic compounds and their uses |
| AU2014240049C1 (en) | 2013-03-14 | 2019-03-07 | Amgen Inc. | Heterocyclic compounds and their uses |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| LT3645002T (lt) | 2017-06-30 | 2025-02-10 | Amgen Inc. | Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais |
| US11040956B2 (en) | 2017-06-30 | 2021-06-22 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| US11608318B2 (en) | 2018-07-12 | 2023-03-21 | Assia Chemical Industries Ltd. | Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl |
| JP2021534138A (ja) * | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| WO2021053189A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220402874A1 (en) | 2019-10-09 | 2022-12-22 | Dr. Reddy's Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| EP4041710A1 (en) | 2019-10-09 | 2022-08-17 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| CA3168513A1 (en) | 2020-02-10 | 2021-08-19 | Amgen Inc. | Omecamtiv mecarbil tablet |
| TW202233189A (zh) | 2020-11-12 | 2022-09-01 | 美商安進公司 | 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法 |
| TW202300479A (zh) | 2021-03-10 | 2023-01-01 | 美商安進公司 | 奧美卡替莫卡必爾之合成 |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2019
- 2019-08-16 JP JP2021507456A patent/JP2021534138A/ja active Pending
- 2019-08-16 MX MX2021001792A patent/MX2021001792A/es unknown
- 2019-08-16 MA MA053226A patent/MA53226A/fr unknown
- 2019-08-16 WO PCT/US2019/046726 patent/WO2020037164A1/en not_active Ceased
- 2019-08-16 CA CA3108800A patent/CA3108800A1/en active Pending
- 2019-08-16 AU AU2019321573A patent/AU2019321573B2/en active Active
- 2019-08-16 EP EP19762026.3A patent/EP3837009A1/en active Pending
- 2019-08-16 US US17/263,224 patent/US11465969B2/en active Active
-
2021
- 2021-02-12 MX MX2023013372A patent/MX2023013372A/es unknown
-
2022
- 2022-09-02 US US17/929,645 patent/US11926592B2/en active Active
-
2024
- 2024-01-18 US US18/416,741 patent/US12612366B2/en active Active
- 2024-06-04 JP JP2024090471A patent/JP2024123028A/ja not_active Withdrawn
-
2025
- 2025-04-14 JP JP2025066074A patent/JP2025108571A/ja active Pending
- 2025-05-29 AU AU2025204014A patent/AU2025204014A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1955697B1 (en) | 2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder | |
| CA2150812C (en) | Catechol diethers as selective pde iv inhibitors | |
| US20120172382A1 (en) | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2005505618A5 (enExample) | ||
| JP2007516218A (ja) | イソキノリノンカリウムチャネル阻害剤 | |
| JP2010523556A5 (enExample) | ||
| ES2404506T3 (es) | Sales hidroxibenzoato de compuestos de metanicotina | |
| JP2005508967A5 (enExample) | ||
| SK6252000A3 (en) | Indazole bioisostere replacement of catechol in therapeutically active compounds | |
| CA2730078A1 (en) | Nitrogen-containing aromatic heterocyclyl compound | |
| US20150313883A1 (en) | Hydroxybenzoate salts of metanicotine compounds | |
| KR20100016593A (ko) | 신규한 바닐로이드 수용체 리간드 및 약제의 제조를 위한 이의 용도 | |
| WO2011002103A2 (en) | A cycloalkane derivative | |
| NZ589019A (en) | 3, 4 - substituted piperidine derivatives as renin inhibitors | |
| MX2014012992A (es) | Derivado de quinazolindiona. | |
| WO2011148956A1 (ja) | 縮合イミダゾール誘導体 | |
| AU2010271746A1 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof | |
| JP2005532397A5 (enExample) | ||
| JP2023530786A5 (enExample) | ||
| US8017785B2 (en) | Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine | |
| JP2007518798A5 (enExample) | ||
| WO2011030864A1 (ja) | アニリン化合物 | |
| WO2007063821A1 (ja) | 光学活性なジヒドロピリジン誘導体の酸付加塩 | |
| JP2009513580A5 (enExample) | ||
| CN107573302B (zh) | 芳基哌嗪化合物及其制备方法和用途 |